Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 269

1.

Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.

Sánchez-Fructuoso AI, Ruiz JC, Torregrosa JV, González E, Gómez E, Gallego RJ, Troya MI, Jimenez C, Llamas F, Romero R, Bernis C, Crespo JF, Guirado L; AnemiaTrans Study Group.

Adv Ther. 2012 Nov;29(11):979-91. doi: 10.1007/s12325-012-0063-3. Epub 2012 Nov 13.

PMID:
23160946
2.

The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.

Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC; BA 16528 Study Investigators.

Clin Nephrol. 2007 May;67(5):306-17.

PMID:
17542340
3.

Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators.

Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. Epub 2007 May 23.

4.

Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.

Sánchez-Escuredo A, Batista F, Cases A, Torregrosa JV.

Transplant Proc. 2015 Jan-Feb;47(1):73-5. doi: 10.1016/j.transproceed.2014.12.006.

PMID:
25645774
5.
6.

Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.

Locatelli F, Villa G, de Francisco AL, Albertazzi A, Adrogue HJ, Dougherty FC, Beyer U; BA16286 Study Investigators.

Curr Med Res Opin. 2007 May;23(5):969-79.

PMID:
17519064
7.
9.

C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.

Kessler M, Martínez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, Beyer U.

Hemodial Int. 2010 Apr;14(2):233-9. doi: 10.1111/j.1542-4758.2009.00421.x. Epub 2009 Nov 3.

PMID:
19888948
10.

C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.

Bastos K, Lucarelli LA, De Francesco-Daher E, Filho RP, Henríquez C, Espinoza B, Villanueva I, Schwedt E, Schiavelli R, Correa-Rotter R.

Int Urol Nephrol. 2013 Oct;45(5):1355-64. doi: 10.1007/s11255-012-0272-3. Epub 2012 Sep 19.

11.

Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia.

Chanu P, Gieschke R, Charoin JE, Pannier A, Reigner B.

J Clin Pharmacol. 2010 May;50(5):507-20. doi: 10.1177/0091270009343931. Epub 2010 Feb 23.

PMID:
20179322
12.

[The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi-center trial].

Chen N, Qian JQ, Mei CL, Zhang AH, Xing CY, Wang L, Liu WH, Wang M, Chen JH, Liu BC, Hou FF, Chen XM, Zuo L, Shi W, Yu LB, Zhang Y.

Zhonghua Nei Ke Za Zhi. 2012 Jul;51(7):502-7. Chinese.

PMID:
22943819
13.

Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease.

Mann JF, de Francisco A, Nassar G, Canaud B.

Clin Nephrol. 2011 Jul;76(1):9-15.

PMID:
21722600
14.

Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study.

Dellanna F, Winkler RE, Bozkurt F, Schettler V, Graf S, Bockreiss N, Fliser D; MIRACEL Study Group.

Int J Clin Pract. 2011 Jan;65(1):64-72. doi: 10.1111/j.1742-1241.2010.02551.x. Epub 2010 Nov 22.

PMID:
21091595
15.

Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.

Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U.

Am J Kidney Dis. 2007 Dec;50(6):989-1000.

PMID:
18037099
16.

Darbepoetin-alfa in renal-transplant patients: an observational monocentric study.

Ribes D, Kamar N, Guitard J, Esposito L, Rostaing L.

Clin Nephrol. 2008 Feb;69(2):102-6.

PMID:
18218303
17.

Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study.

de Francisco AL, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, Dougherty FC, Oguey D; BA16260 Study Invesigators.

Int J Clin Pract. 2006 Dec;60(12):1687-96. Erratum in: Int J Clin Pract. 2007 Oct;61(10):1776-7.

PMID:
17109676
18.

C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease.

Locatelli F, Mann JF, Aldigier JC, Sanz Guajardo D, Schmidt R, Van Vlem B, Sulowicz W, Dougherty FC, Beyer U.

Clin Nephrol. 2010 Feb;73(2):94-103.

PMID:
20129016
19.

Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients.

Weinreich T, Leistikow F, Hartmann HG, Vollgraf G, Dellanna F; SESAM Study Group.

Hemodial Int. 2012 Jan;16(1):11-9. doi: 10.1111/j.1542-4758.2011.00608.x.

PMID:
22098689
20.

[Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].

Jelić I, Lovcić V, Kurtović I, Josipović M, Havranek Z, Kostić L, Racki S.

Acta Med Croatica. 2012 Jul;66(3):157-64. Croatian.

PMID:
23441529

Supplemental Content

Support Center